Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edgewise Therapeutics, Inc. (EWTX : NSDQ)

• Company Description    Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $7.28 Daily Weekly Monthly 20 Day Moving Average: 213,538 shares Shares Outstanding: 49.58 (millions) Market Capitalization: $360.91 (millions) Beta: -0.11 52 Week High: $29.75 52 Week Low: $6.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.45% 1.97% 12 Week -39.48% -33.48% Year To Date -52.36% -44.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3415 COLORADO AVE. - BOULDER,CO 80303 USA ph: 720-262-7002 fax: - ir@edgewisetx.com http://www.edgewisetx.com

• General Corporate Information    Officers Kevin Koch - President; Chief Executive Officer and Director Peter Thompson - Chairman and Director R. Michael Carruthers - Chief Financial Officer Alan Russell - Chief Scientific Officer and Director Laura A. Brege - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28036F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 49.58 Most Recent Split Date: (:1) Beta: -0.11 Market Capitalization: $360.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -114.29% vs. Previous Quarter: -15.38% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -18.14 12/31/21 - -12.46 09/30/21 - -13.97 ROA 03/31/22 - -17.53 12/31/21 - -12.13 09/30/21 - -11.48 Current Ratio 03/31/22 - 26.85 12/31/21 - 26.97 09/30/21 - 33.50 Quick Ratio 03/31/22 - 26.85 12/31/21 - 26.97 09/30/21 - 33.50 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 5.25 12/31/21 - 5.57 09/30/21 - 5.79 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©